Analysis Life Sciences Thank You The FDA and oncology: 2023 year in review
Agency IQ
DECEMBER 11, 2023
In 2015, the FDA, along with the American Association for Cancer Research (AACR), held a workshop on dose optimization for small molecules. Despite challenges in enrolling pediatric patients with rare cancers in trials, KRISTEN WESSEL of the FDA’s Division of Clinical Pharmacology recently argued that it’s not impossible.
40 
Let's personalize your content